Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd D Gould

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
Genes, Brain, and Behavior|September 30, 2016
Irving I. Gottesman (1930-2016): the multifactorial threshold model of complex phenotypes mediated by endophenotype strategiesTodd D Gould
Expert Opinion on Therapeutic Targets|May 19, 2006
Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medicationsTodd D Gould
Neuroscience and Biobehavioral Reviews|July 14, 2007
Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvementTodd D Gould, Haim Einat
Biological Psychiatry|November 28, 2017
Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant ActionsPanos Zanos, Todd D Gould
Journal of Psychosomatic Research|August 10, 2002
Signaling networks in the pathophysiology and treatment of mood disordersTodd D Gould, Husseini K Manji
The American Journal of Psychiatry|April 2, 2003
The endophenotype concept in psychiatry: etymology and strategic intentionsIrving I Gottesman, Todd D Gould
Biological Psychiatry|October 19, 2025
Intermittent Ketamine and Neuromodulation Treatment Evoke Synergistic Antidepressant-Relevant ActionKyle A Brown, Todd D Gould
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 24, 2023
Disassociating drug active ingredients from inactive: ketamine-like synaptic effects of a ketamine excipientKyle A Brown, Todd D Gould
Annual Review of Clinical Psychology|February 9, 2021
Ketamine and the Future of Rapid-Acting AntidepressantsLace M Riggs, Todd D Gould
Science (New York, N.Y.)|February 16, 2023
Possible psychedelic therapeutic mechanismEvan M Hess, Todd D Gould
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Genes, Brain, and Behavior|September 30, 2016
Irving I. Gottesman (1930-2016): the multifactorial threshold model of complex phenotypes mediated by endophenotype strategiesTodd D Gould
Expert Opinion on Therapeutic Targets|May 19, 2006
Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medicationsTodd D Gould
Neuroscience and Biobehavioral Reviews|July 14, 2007
Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvementTodd D Gould, Haim Einat
Biological Psychiatry|November 28, 2017
Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant ActionsPanos Zanos, Todd D Gould
Journal of Psychosomatic Research|August 10, 2002
Signaling networks in the pathophysiology and treatment of mood disordersTodd D Gould, Husseini K Manji
The American Journal of Psychiatry|April 2, 2003
The endophenotype concept in psychiatry: etymology and strategic intentionsIrving I Gottesman, Todd D Gould
Biological Psychiatry|October 19, 2025
Intermittent Ketamine and Neuromodulation Treatment Evoke Synergistic Antidepressant-Relevant ActionKyle A Brown, Todd D Gould
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 24, 2023
Disassociating drug active ingredients from inactive: ketamine-like synaptic effects of a ketamine excipientKyle A Brown, Todd D Gould
Annual Review of Clinical Psychology|February 9, 2021
Ketamine and the Future of Rapid-Acting AntidepressantsLace M Riggs, Todd D Gould
Science (New York, N.Y.)|February 16, 2023
Possible psychedelic therapeutic mechanismEvan M Hess, Todd D Gould
Pageof 13